

Pranshu Bansal, M.D.
Ironwood Cancer and Research Centers
Division of Oncology and Hematology
Lung, Head & Neck Malignancies

Education:

- 08/2014- 08/2017 University of New Mexico, Albuquerque, NM
 Fellowship in Hematology/Oncology
- 07/2011-06/2014 University of Missouri Hospital and Clinics, Columbia, MO
 Residency in Internal Medicine
- 08/2004-03/2010 Vardhman Mahavir Medical College and Safdarjung Hospital
 New Delhi- India
 M.B.B.S. (Bachelor of Medicine, Bachelor of Surgery)

Professional Experience:

- 03/2021 – Present Ironwood Physicians, PC
- 08/2017- 03/2021 Staff Physician - New Mexico Cancer Center, Albuquerque, NM
- 06/2018- 03/2021 Clinical Assistant Professor Burrell College of Osteopathic Medicine, Las Cruces, NM
- 12/2017-03/2021 Director of clinical research/Phase 2/3 clinical trial program at New Cancer Center, Albuquerque NM
- 01/2015- 02/2016 Research Associate- Dr Yanis Bumber Lab/ University Of New Mexico, Albuquerque NM worked on “role of Musashi2 in lung cancer progression and resistance to chemotherapy”
- 10/2010- 03/2011 Lab Research Assistant- Dr Robert Hromas Lab/ University of New Mexico, Albuquerque, NM, worked on “role of histone deacetylase in peripheral T Cell leukemia”

Activities and Honors:

Certifications:

10/2017- American Board of Internal Medicine- Hematology
10/2017- American Board of Internal Medicine- Oncology
10/2014- American Board of Internal Medicine

Awards, Honors and Committees:

2007- Distinction in Professional I- Physiology
2004- State Winner National Science Olympiad in Chemistry, India

Professional Memberships:

HLH society of America	2017- Present
American Association for Cancer Research	2017- Present
American Society of Clinical Oncology	2014- Present
American Society of Hematology	2014-Present
Indian Red Cross	2010- Present

Publications:

Articles in peer-reviewed journals

Loo E, **Bansal P**, Cherukuri D, Arana Yi C Isodicentric Philadelphia chromosome: an uncommon chromosomal abnormality in the chronic phase of chronic myeloid leukemia (CML). *Clinical case Reports*. Nov 19 2015 PMID 2678434

Bansal P, Osman D, Gan G, Simon GR, Bumber Y. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. *Frontiers in Oncology* 6 (2016). PMID 27200298.

Bansal P, Rusthoven C, Bumber Y, Gan GN. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. *Future oncology (London, England)* . PMID 27467543

Bansal P, Osman D, Simon G, Gan GN, Bumber Y Recent advances in immunotherapy in NSCLC. *Frontiers in oncology* May 2016 PMID 27200298.

Hu S, **Bansal P**, Lynch D, Hernandez CMR, Dayao Z. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature. *Journal of Medical Case Reports*. Dec 20 2016 PMID 27998299

Castresana D, **Bansal P**, Vasef MA, Kapoor V, Leone C, Quintana D. Aggressive lymphoma presenting as dysphagia: A rare cause of dysphagia. *Clinical case repots*. March 13 2017. PMID 28469848

Marchio S, **Bansal P**, Pasqualini R, Arap W. An antivascular vaccine to boost self-immunity and strike the tumor. Proceedings of National Academy of Science. Apr 18 2017 PMID 28400521

Patt YZ, Murad W, Fekrazad M, Baron A, **Bansal P**, Boucher Y, Steinberg K, LEE S-J, Bedrick E, Du R, Lee FC. INST OX-05-024: First Line Gemcitabine, Oxaliplatin and Erlotinib for Primary Hepatocellular Carcinoma (HCC) and Bile Duct Cancers (BDC): A multicenter Phase II Trial. Cancer Medicine. Aug 11 2017. PMID 28801995

PATT YZ, Hernandez RC, Fekrazad H, **Bansal P**, Lee FC. Phase II trial of sorafenib in combination with capecitabine in patients with hepatocellular carcinoma: INST 08-20. The Oncologist June 1 2017. PMID 28687627

Araujo Mino EP, Patt YZ, Murray-Crean C, Hanson JA, **Bansal P**, Liem BJ, Rajput A, Fekrazad MH, Heywood G, Lee FC. Phase II trial using a combination of Capecitabine, Oxaliplatin and Celcoxib with concurrent Radiation for newly diagnosed Resectable Rectal cancer. The Oncologist November 20 2017. PMID 29153865

Hilal T, **Bansal P**, Kelemen K, Slack J. Nivolumab associated bone marrow necrosis. Annals of oncology February 1 2018. PMID 29351576

Arora S, Velichinskii R, Lesh WR, Ali U, Kubaik M, **Bansal P**, Borghaei H, Edelman MJ, Boucher Y- Existing and emerging role for checkpoint Immunotherapy in solid tumors- Advances in therapy October 2019 Volume 36, Issue 10 pp 2638-2678. PMID 31410780

Qeadan F; **Bansal P**; Hanson JA; Beswick E “The MK2 pathway is linked to G-CSF, cytokine production and metastasis in gastric cancer: a novel intercorrelation analysis approach” Journal of translational medicine volume 18, Article number: 137 (2020) PMID 32216812

Shaheen MF, Julie TY, Sokol SE, Masterson M, **Bansal P**, Ian Rabinowitz, Arap W et al “Genomic landscape of lymphatic malformations: a case series and response to the PI3K α inhibitor alpelisib in an N-of-1 clinical trial” Journal E Life Sciences June 7 2022 PMID 35787844

Book Chapters

Williamson EA, Wray JW, **Bansal P**, Hromas R. Overview for the histone codes for DNA repair. Prog Mol Biol Transl Sci. 2012;110:207-27.

Research Trials:

Sub investigator in Ironwood Cancer and Research Centers trials, please refer to website for details.

Other Activities:

Tennis, skiing, hiking